[Articles] Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial

Di |2024-08-10T00:30:01+02:00Agosto 10th, 2024|Categorie: Coronavirus Lancet|

A regimen consisting of 2 days of intraurethral LBP-EC01 and 3 days of concurrent intravenous LBP-EC01 (1 × 1010 PFU) and oral TMP–SMX twice a day was well tolerated, with consistent pharmacokinetic profiles in urine and blood. LBP-EC01 and TMP–SMX dos...

[Personal View] The panzootic spread of highly pathogenic avian influenza H5N1 sublineage 2.3.4.4b: a critical appraisal of One Health preparedness and prevention

Di |2024-08-10T00:30:01+02:00Agosto 10th, 2024|Categorie: Coronavirus Lancet|

Changes in the epidemiology and ecology of H5N1 highly pathogenic avian influenza are devastating wild bird and poultry populations, farms and communities, and wild mammals worldwide. Having originated in farmed poultry, H5N1 viruses are now spread glo...

[Personal View] The panzootic spread of highly pathogenic avian influenza H5N1 sublineage 2.3.4.4b: a critical appraisal of One Health preparedness and prevention

Di |2024-08-10T00:30:01+02:00Agosto 10th, 2024|Categorie: Coronavirus Lancet|

Changes in the epidemiology and ecology of H5N1 highly pathogenic avian influenza are devastating wild bird and poultry populations, farms and communities, and wild mammals worldwide. Having originated in farmed poultry, H5N1 viruses are now spread glo...

[Articles] Efficacy and safety of Butantan-DV in participants aged 2–59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil

Di |2024-08-05T18:30:02+02:00Agosto 5th, 2024|Categorie: Coronavirus Lancet|

A single dose of Butantan-DV was generally well tolerated and efficacious against symptomatic VCD (caused by DENV-1 and DENV-2) for a mean of 3·7 years. These findings support the continued development of Butantan-DV to prevent dengue disease in childr...

[Articles] Efficacy and safety of Butantan-DV in participants aged 2–59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil

Di |2024-08-05T18:30:02+02:00Agosto 5th, 2024|Categorie: Coronavirus Lancet|

A single dose of Butantan-DV was generally well tolerated and efficacious against symptomatic VCD (caused by DENV-1 and DENV-2) for a mean of 3·7 years. These findings support the continued development of Butantan-DV to prevent dengue disease in childr...

[Correspondence] Tracking the spread of avian influenza A(H5N1) with alternative surveillance methods: the example of wastewater data

Di |2024-08-03T00:30:01+02:00Agosto 3rd, 2024|Categorie: Coronavirus Lancet|

The global health landscape is currently dominated by the threat of avian influenza, a public health challenge of unprecedented magnitude. We are on the brink of a potential crisis, where pandemic risk is severely underestimated and efforts to prepare ...

[Correspondence] Tracking the spread of avian influenza A(H5N1) with alternative surveillance methods: the example of wastewater data

Di |2024-08-03T00:30:01+02:00Agosto 3rd, 2024|Categorie: Coronavirus Lancet|

The global health landscape is currently dominated by the threat of avian influenza, a public health challenge of unprecedented magnitude. We are on the brink of a potential crisis, where pandemic risk is severely underestimated and efforts to prepare ...

[Articles] Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial

Di |2024-08-02T00:30:01+02:00Agosto 2nd, 2024|Categorie: Coronavirus Lancet|

Treatment with either dose of fosravuconazole was not superior to itraconazole, and the two doses had a numerically lower efficacy. However, fosravuconazole presented no new safety signals, and its lower pill burden and reduced risk of drug–drug intera...

Torna in cima